Cormorant Asset Management, LP Eye Point Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $1.43 Billion
- Q3 2024
A detailed history of Cormorant Asset Management, LP transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 8,325,000 shares of EYPT stock, worth $59.1 Million. This represents 4.66% of its overall portfolio holdings.
Number of Shares
8,325,000
Previous 8,325,000
-0.0%
Holding current value
$59.1 Million
Previous $72.4 Million
8.16%
% of portfolio
4.66%
Previous 5.57%
Shares
5 transactions
Others Institutions Holding EYPT
# of Institutions
150Shares Held
58MCall Options Held
177KPut Options Held
263K-
Suvretta Capital Management, LLC New York, NY5.18MShares$36.7 Million1.63% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$28.5 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.79MShares$26.9 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$26.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.05MShares$21.6 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $242M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...